ClinicalTrials.gg
RecruitingNCT05543798VISABL-VTUpdated Nov 10, 2026

VT Ablation in the iCMR

An interventional study of Vision-MR Ablation Catheter 2.0 in Ventricular Tachycardia, sponsored by Imricor Medical Systems. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Imricor Medical Systems · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.
Updated Nov 10, 2026Site recruiting status changedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Tachycardia, Ventricular with a site in Netherlands — 10 open to participants now, 11 under way, none of them phase 3. Tachycardia, Ventricular · Netherlands.

Planned enrollment
15th of 19
64 · median 270
Started
2025
with 1 other
No phase
13 of 34
4 open now
Primary completion
2027-07
later than 4 of 10 live
Registered
29th of 34
by date

Among the 34 studies in Tachycardia, Ventricular with a site in Netherlands, this one is the 15th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2025, is one of 13 with no phase, reaches primary completion later than 4 of the 10 other live ones, and was the 29th registered.

Tachycardia, Ventricular

452 studies on the registry are indexed under Tachycardia, Ventricular; 121 are open to participants now.

Browse Tachycardia, Ventricular studies →

Open to participants now

10 of the 34 studies in Tachycardia, Ventricular with a site in Netherlands are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 86 Tachycardia, Ventricular studies recruiting now, 67 (78%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Tachycardia, Ventricular with a site in Netherlands, or all of them as a file.
02

Study summary

The VISABL-VT is a prospective, single-arm, multi-center, interventional investigation of the safety and efficacy of radiofrequency (RF) ablation of ventricular tachycardia associated with ischemic cardiomyopathy performed with the Vision-MR Ablation Catheter 2.0 in the iCMR environment.

03

Conditions studied

  • Ventricular Tachycardia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Roll-in subjects only: Documentation of premature ventricular contractions indicated for ablation therapy (subjects may or may not be diagnosed with Ischemic Cardiomyopathy)
  • Documented (/EGM) spontaneous episode of sustained ventricular tachycardia within 6 months of the procedure
  • Diagnosis of Ischemic Cardiomyopathy
  • AAD therapy , , not tolerated, or not desired
  • 18 years or older

Exclusion criteria

Exclusion Criteria:

  • Implanted with non-MR compatible medical devices or for an MRI
  • Presence of intracardiac thrombus (verified via CT/MRI/TEE/TTE within 48 hours of procedure - or at start of procedure)
  • Thrombocytopenia or coagulopathy
  • Mechanical mitral and/or aortic valve precluding access to the left ventricle
  • Severe aortic stenosis
  • Myocardial infarction requiring stent implantation within 90 days of procedure
  • Previous cardiac surgery within 60 days of procedures
  • Known/uncontrolled stroke risks
  • Class IV Heart Failure
  • (EF) \< 25%
  • Patients with a (GFR) \< 30
  • Women who are pregnant
  • Allergy to contrast agents (e.g., Gadolinium)
  • Active infection
  • Known or suspected myxoma
  • Unstable angina
  • Patients who do not tolerate anticoagulation therapy
  • Previous intertribal septal patch or prosthetic atrial septal defect closure device
  • \< 12 months
  • Enrollment in another study without sponsor approval
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Non-Randomized

    All subjects with ventricular tachycardia associated with ischemic cardiomyopathy will undergo catheter ablation using the Vision-MR Ablation Catheter 2.0

    Device: Vision-MR Ablation Catheter 2.0

Interventions

  • DeviceVision-MR Ablation Catheter 2.0

    Catheter ablation of ventricular tachycardia

06

What researchers measure

Primary outcomes

  1. Primary Efficacy Endpoint

    Absence of inducible clinical ventricular tachycardia (VT) following the last RF application with with the Vision-MR Ablation Catheter 2.0

    Time frame: Perioperative/Periprocedural

  2. Primary Safety Endpoint

    Composite of any procedure or device related serious adverse events through 7 days post index ablation procedure

    Time frame: 7 days

Secondary outcomes

  1. Secondary Efficacy Endpoint

    Chronic success defined as 6-month freedom from recurrence of sustained VT or VT requiring intervention and freedom from new or increased dose of Class I or III antiarrhythmic drugs (AAD) at 6 months following the index ablation procedure.

    Time frame: 6 months

07

Study locations

2 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Jul 2027, 27 months after the start.

Of 40 industry-sponsored interventional studies with no phase under Tachycardia, Ventricular, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 52. This study's planned 27 months is below that.

Counting every sponsor, half of 126 studies reached it within 36 months; a quarter within 20 and three quarters within 66.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Dec 2026 → Jul 2027 and completion Jun 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2022
First posted
Sep 16, 2022
StartActual
Apr 10, 2025
Primary completionEst.
Jul 2027was Dec 2026
CompletionEst.
Dec 2027was Jun 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
HagaZiekenhuis is now Recruiting
Nov 10, 2026
Primary completion
Dec 2026→Jul 2027
Nov 10, 2026
Study completion
Jun 2027→Dec 2027
Nov 10, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • HagaZiekenhuis · The Hague, NetherlandsContact none listed→i•••@hagaziekenhuis.nl
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    HagaZiekenhuis is now Recruiting
    Primary completion Dec 2026→Jul 2027
    Study completion Jun 2027→Dec 2027
    Site contacts Changed at 1 site. See the sites
    Show the site
    • HagaZiekenhuis · The Hague, NetherlandsContact none listed→i•••@hagaziekenhuis.nl
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05543798
Lead sponsor
Imricor Medical Systems
Responsible party
Sponsor
First posted
Sep 16, 2022
Start date
Apr 10, 2025
Primary completion
Jul 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Kate Lindborg, Phd
Contact
kate.lindborg@imricor.com
9528188400

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion